Colesevelam is a bile acid sequestrant that is an FDA approved drug to be used in adjunct with diet and exercise for a variety of indications. The main indication is to lower an elevated low-density lipoprotein cholesterol (LDL-C) in patients with primary hyperlipidemia and other diseases that cause hyperlipidemia. It can be used as a monotherapy or with an HMG-CoA reductase inhibitor (statin), ezetimibe or niacin, or in a three- or a four-drug combination. Another approved use is to reduce LDL-C levels in boys and postmenarchal girls ages 10-17 who have heterozygous familial hypercholesterolemia. For this situation, colesevelam can be used as a monotherapy or with a statin only after a proper trial of diet and exercise has failed. Finally, the last FDA approved indication is to improve glycemic control in type 2 diabetic adults.
While not an FDA approved use, colesevelam has shown to improve stool consistency in patients who have irritable bowel syndrome with diarrhea, causing an overall improvement in bowel function. Overall effects were consistent with increased hepatic bile synthesis and luminal bile acid sequestration by colesevelam.
Colesevelam is a novel drug created to help patients lower their LDL cholesterol levels. Its primary mechanism of action is to create nonabsorbable complexes when exposed to bile acids in the GI tract. It forms these complexes due to its numerous hydrophobic side chains, which enhances the binding of bile acids. Once it forms the complexes, the bile acids are no longer able to be reabsorbed to participate in the enterohepatic bile acid recirculation system. This activity causes a reduction in the total amount of bile acids in the body, causing an upregulation of 7-alpha-hydroxylase enzyme that is responsible for converting intracellular cholesterol into bile acids. With the need for bile acids increased, hepatic LDL receptors become upregulated to provide enough cholesterol for bile acid synthesis. As more and more cholesterol diverts into creating bile acids, there is an overall decrease in the plasma LDL cholesterol level, along with a decrease in total cholesterol levels.
The main mechanism through which colesevelam reduces plasma glucose levels is not entirely understood. In animal studies, researchers have observed colesevelam to increase the levels of the hormone glucagon-like peptide-1, GLP-1, and other incretins. Mice models show that this occurs through the activation of TGR5 secondary to the binding of bile acids in the GI tract. Once GLP1 and other incretins are activated, overall hepatic glycogenolysis becomes suppressed. This suppression occurs because patients with type 2 diabetes have increased hepatic production of glucose, contributing to elevated fasting serum glucose levels. By decreasing hepatic glycogenolysis, one can expect a reduction in serum glucose levels.
Colesevelam comes in three major forms that are available to patients. Healthcare providers have the option to chose from an oral tablet formulation, a prepared suspension, as well as a recently approved chewable bar form. The recommendation is to take either once or twice daily to achieve therapeutic effects. Also, patients with susceptibility to fat-soluble vitamin and folic acid deficiencies should take the vitamins at least 4 hours after taking colesevelam to allow for proper absorption of the vitamins. This principle also applies to statins. Statins need to be taken at least 4 hours after taking colesevelam. Patients should be counseled on proper fluid intake once started on colesevelam.
Colesevelam comes in the following formulations:
Colesevelam is part of the drug class known as bile acid sequestrants. While overall, very effective and safe to use as a nonsystemic approach to lower cholesterol, tolerability, and compliance issues are not uncommon. Colesevelam has the lowest rate of side effects associated with its use, but it still shares the same side effects as the rest of the drugs in its class. Due to the mechanism of action and causing increased bile acid in the gastrointestinal tract, the predominant side effects are gastrointestinal. Symptoms like constipation, diarrhea, gas, as well as nausea, abdominal pain, and weakness, are common. Patients have also noted muscle pain to be a side effect of colesevelam. Other notable side effects associated with the use of colesevelam is a significant increase in triglycerides. Also, steatorrhea is a common side effect of these drugs as well. Due to this, patients should receive counsel to take this drug at least four hours before vitamin supplements, as well as statins.
Colesevelam may decrease the bioavailability of many drugs including but not limited to: amiodarone, oral corticosteroids, cyclosporine (systemic), estrogen derivatives, progesterone, oral contraceptives, ezetimibe, glimepiride, glipizide, glyburide, leflunomide, lomitapide, loop diuretics like furosemide, thiazides, methotrexate, mycophenolate, nonsteroidal anti-inflammatory drugs, olmesartan, phenytoin, pravastatin, niacin, propranolol, raloxifene, tetracyclines, levothyroxine, ursodiol, oral vancomycin, warfarin and fat-soluble multivitamins A, E, D, K. If these drugs are on the treatment regimen of the patient, monitor therapy or consider therapy modification. These drugs require administration either one to two hours before or four hours after colesevelam administration (see product information of the medications mentioned above).
Colesevelam, while a generally well-tolerated drug with relatively mild side effects, does still have a few side effects that healthcare providers should know and be aware of before prescribing a patient the medication. Clinicians should not give colesevelam to patients with a history of bowel obstruction. Additionally, patients with a history of serum triglyceride concentrations greater than 500mg/dL or a history of hypertriglyceridemia-induced pancreatitis should not be given this drug due to its ability to increase triglyceride levels.
Colesevelam has relatively few monitoring needs. While the desired effect of the drug is easily attainable without monitoring, the real monitoring that is necessary is with concomitantly administered drugs. Colesevelam primarily has been shown to decrease levels of fat-soluble vitamins as the drug tends to cause steatorrhea and the malabsorption of these vitamins. Patients with known deficiencies of these vitamins should understand to take their supplements either an hour before or about four hours after the administration of colesevelam. In addition to fat-soluble vitamins, studies have shown that patients with hypothyroidism that get started on colesevelam show an increase in TSH levels. This increase indicates that colesevelam causes a decreased absorption to levothyroxine. To counter this, healthcare providers should monitor the patient's TSH levels while on this drug and advise patients to take their levothyroxine four hours after having taken colesevelam. Lastly, patients with triglycerides above 300 mg/dL should be given this drug with caution. Due to colesevelam's side effect of increasing triglyceride levels, patients with already elevated levels above 300 mg/dL are at risk for increased adverse events like triglyceride-induced pancreatitis and other adverse effects associated with high triglyceride levels.
Overall, colesevelam is a very safe drug to use with a long history of clinical use and study. The medication does not cause toxicity outside of the adverse effects mentioned above. Healthcare providers should be on the lookout for adverse effects patients may experience and work with the clinical care team as well as the patient to see if the medication needs to be adjusted or changed to help alleviate the adverse effects. Healthcare providers should also consider the use of an alternative formulation of the drug if there are side effects, especially gastrointestinal side effects.
Colesevelam is a very safe drug in the class of bile acid sequestrants used for the treatment of various illnesses. While very safe to use, adverse events are possible. As such, all members of the healthcare team should be on the lookout for the adverse effects. Also, members of the team should be knowledgeable on the drug and its properties to help advise the patient on the proper information they should know when taking the medication. Physicians can utilize pharmacist expertise if there is a question on whether the patient can take the drug safely or not, as well as verifying if any contraindications or drug-to-drug interactions might exist. Nursing can provide essential information to patients as well as education on common side effects. Also, nursing can monitor the common adverse effects, as well as serious side effects that patients may experience and may require medical attention. Every member of the interprofessional healthcare team has a responsibility to provide the best care to their patients and should be aware of therapies they might be on to help achieve the best possible outcome for the patient.
|||Camilleri M,Acosta A,Busciglio I,Boldingh A,Dyer RB,Zinsmeister AR,Lueke A,Gray A,Donato LJ, Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome. Alimentary pharmacology [PubMed PMID: 25594801]|
|||Nwose OM,Jones MR, Atypical mechanism of glucose modulation by colesevelam in patients with type 2 diabetes. Clinical medicine insights. Endocrinology and diabetes. 2013 Dec 8; [PubMed PMID: 24348081]|
|||Sonnett T,Robinson J,Milani P,Campbell RK, Role of colesevelam in managing heterozygous familial hypercholesterolemia in adolescents and children. Adolescent health, medicine and therapeutics. 2010; [PubMed PMID: 24600261]|
|||Patient tolerance and acceptance of colesevelam hydrochloride: focus on type-2 diabetes mellitus., Brunetti L,DeSantis EH,, P & T : a peer-reviewed journal for formulary management, 2015 Jan [PubMed PMID: 25628509]|
|||Zema MJ, Colesevelam hydrochloride: evidence for its use in the treatment of hypercholesterolemia and type 2 diabetes mellitus with insights into mechanism of action. Core evidence. 2012; [PubMed PMID: 22936894]|
|||Aggarwal S,Loomba RS,Arora RR, Efficacy of colesevelam on lowering glycemia and lipids. Journal of cardiovascular pharmacology. 2012 Feb; [PubMed PMID: 21983746]|
|||Bays H,Jones PH, Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors. Vascular health and risk management. 2007; [PubMed PMID: 18078024]|
|||Sekhri K,Saha L, Colesevelam hydrochloride: A novel agent in patients with type 2 diabetes. International journal of applied [PubMed PMID: 23776789]|
|||Weitzman SP,Ginsburg KC,Carlson HE, Colesevelam hydrochloride and lanthanum carbonate interfere with the absorption of levothyroxine. Thyroid : official journal of the American Thyroid Association. 2009 Jan; [PubMed PMID: 19119983]|
|||Kaufman MB, Drug-induced pancreatitis: A Potentially Serious and Underreported Problem. P [PubMed PMID: 23946630]|